within Pharmacolibrary.Drugs.ATC.D;

model D05AX05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00013333333333333334,
    adminDuration  = 600,
    adminMass      = 5.0 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D05AX05</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tazarotene is a third-generation topical retinoid prodrug used primarily for the treatment of psoriasis, acne vulgaris, and photoaged skin. It is approved for medical use, mainly in topical gel or cream formulations, and acts through modification of gene expression via retinoic acid receptors.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult patients, as currently available clinical literature provides only limited systemic exposure data due to the primarily topical administration and extensive first-pass metabolism. No robust compartmental PK modeling is published for tazarotene.</p><h4>References</h4><ol><li><p>Heath, MS, et al., &amp; Feldman, SR (2018). Pharmacokinetics of tazarotene and acitretin in psoriasis. <i>Expert opinion on drug metabolism &amp; toxicology</i> 14(9) 919–927. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2018.1515198&quot;>10.1080/17425255.2018.1515198</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30134735/&quot;>https://pubmed.ncbi.nlm.nih.gov/30134735</a></p></li><li><p>Tang-Liu, DD, et al., &amp; Usansky, JI (1999). Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. <i>Clinical pharmacokinetics</i> 37(4) 273–287. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199937040-00001&quot;>10.2165/00003088-199937040-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10554045/&quot;>https://pubmed.ncbi.nlm.nih.gov/10554045</a></p></li><li><p>Foster, RH, et al., &amp; Benfield, P (1998). Tazarotene. <i>Drugs</i> 55(5) 705–712. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199855050-00008&quot;>10.2165/00003495-199855050-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9585866/&quot;>https://pubmed.ncbi.nlm.nih.gov/9585866</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D05AX05;
